Molecular Controls

Human-like low noise controls to deliver superior test LOD

SensID BDXXP4 n-cfDNA (shaded Pink) exhibits DNA size distributions closer to the resemblance of healthy donor (HD) cfDNA. ++ISMRC Poster 2023: Use of a highly sensitive minimal residual disease test to characterize novel cell-free DNA reference material

Human-like cfDNA Profile

Quality Controls & Reference Standards for molecular diagnostics:

Human-Like: BDXXP4 n-cfDNA resembles HD cfDNA

Customized: Tailored to your diagnostic DNA marker needs

Accurate: Homogeneous synthetic DNA mutation profile mixed with WT background

Scalable: An unlimited resource

Relevant: human origin products

Optimize and validate your assay performance

Calibrate NGS, PCR, or sample preparation instruments

Monitor daily assay performance

Cancercontrols.com is proud to serve as the exclusive business development and distribution partner for SensID products within the U.S. and Canada.

A comparison of mean error rate determined for different cfDNA-like RMs vs healthy donor (HD) cfDNA using clinical lab minimal residual (MRD) test. ++ISMRC Poster 2023: Use of a highly sensitive minimal residual disease test to characterize novel cell-free DNA reference material

Superior Low-Noise Reference Materials

Accurate: Homogeneous precision made mutation profile

Scalable: An unlimited resource

Low-noise: Improved false positivity rate for enhanced LOD

Optimize and validate assay performance

Calibrate NGS, PCR, or sample preparation instruments

Diverse Genetic Modifications

Choose from a broad range of genetic modifications

Point Mutations

Insertions

Deletions

Amplifications

Translocations

Molecular Control Products

Multiple formats, tailored, platform agnostic solutions available, including custom solutions as well as off-the-shelf products.

Categories: gDNA, cfDNA/ctDNA, Plasma and FFPE

Low-noise: Improved false positivity rate for enhanced LOD

Formats: low/medium/and high allelic frequency (e.g. for Liquid Biopsy applications)

Quality System: Manufactured under ISO 13485: 2016

Negative Controls: Serum Certified DNA free for liquid biopsy procedures

References

ISMRC Poster 2023: Use of a highly sensitive minimal residual disease test to characterize novel cell-free DNA reference material.
Annett Helfrich-Kröger¹, Stefanie Kasielke¹, Robert Querfurth¹, Matt Ryder², Daniel Mehnert¹, Fabian Wiggers¹, Anna-Maria Pielka³, Björn Nowack³ and Frank Holtrup¹
¹Haystack Oncology GmbH, ²Haystack Oncology, Inc., ³SensID GmbH

Molecular diagnostic workflow evaluations: Sensitivity assessment of workflows detecting rare circulating cell-free DNA targets: A study design proposal.
AVoss T, Ullius A, Schönborn M, Oelmüller U. PLoS One. 2021 Jul 6;16(7):e0253401

Molecular pathology proficiency studies (ring trials): Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue. Virchows Arch. Vollbrecht C, Hoffmann I, Lehmann A, Merkelbach-Bruse S, Fassunke J, Wagener-Ryczek S, Ball M, Dimitrova L, Hartmann A, Stöhr R, Erber R, Weichert W, Pfarr N, Bohlmann L, Jung A, Dietmaier W, Dietel M, Horst D, Hummel M.
2022 Nov 11. doi: 10.1007/s00428-022-03445-x